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While in vitro studies have demonstrated that a glucocorticoid receptor (GR) splice isoform, -isoform of human GR (hGR),
acts as a dominant-negative inhibitor of the classic hGR and confers glucocorticoid resistance, the in vivo function of hGR is
poorly understood. To this end, we created an adeno-associated virus (AAV) to express hGR in the mouse liver under the con-
trol of the hepatocyte-specific promoter. Genome-wide expression analysis of mouse livers showed that hGR significantly in-
creased the expression of numerous genes, many of which are involved in endocrine system disorders and the inflammatory re-
sponse. Physiologically, hGR antagonized GR’s function and attenuated hepatic gluconeogenesis through downregulation of
phosphoenolpyruvate carboxykinase (PEPCK) in wild-type (WT)mouse liver. Interestingly, however, hGR did not repress
PEPCK in GR liver knockout (GRLKO)mice. In contrast, hGR regulates the expression of STAT1 in the livers of bothWT and
GRLKOmice. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays demonstrated that hGR binds to the in-
tergenic glucocorticoid response element (GRE) of the STAT1 gene. Furthermore, treatment with RU486 inhibited the upregula-
tion of STAT1mediated by hGR. Finally, our array data demonstrate that hGR regulates unique components of liver gene
expression in vivo by both GR-dependent and GR-independent mechanisms.
Glucocorticoids, the end products of the hypothalamic-pitu-itary-adrenal axis, are primary stress hormones that are es-
sential for life. They are released into the circulation in response to
environmental and physiological stress and regulate basal and
stress-related homeostasis. The physiological and pharmacologi-
cal actions of glucocorticoids are mediated by the ubiquitously
expressed glucocorticoid receptor (GR) (NR3C1), a hormone-
binding transcription factor of the nuclear receptor superfamily.
The cellular response to glucocorticoids exhibits great variability
in terms of sensitivity and specificity among individuals and even
within tissues of the same individual. This diversity is mediated, at
least in part, by multiple GR isoforms arising from alternative
processing of the GR gene (1). The individual GR isoforms have
unique expression and gene regulation profiles under specific
physiological conditions (2). Since glucocorticoid signaling pro-
files reflect a comprehensive effect of all transcriptional and trans-
lational GR isoforms available in a given cell or a specific tissue, it
is essential to understand the physiological role of each individual
GR isoform in animal models.
The human glucocorticoid receptor gene consists of 9 exons.
Alternative splicing in the C-terminal exon 9 produces the hor-
mone-binding -isoform of human GR (hGR) and a non-hor-
mone-binding splice isoform, hGR. While hGR is the classic
receptor andmediatesmost of the known actions of glucocortico-
ids, the physiological actions of hGR have not been explored in
vivo. hGR shares the first 727 amino acids with hGR, covering
theN-terminal domain (NTD) andDNAbinding domain (DBD).
From the point of divergence at amino acid 728, hGR contains
an additional 50 amino acids forming a complete ligand binding
domain (LBD), whereas the splice variant hGR encodes only an
additional 15 nonhomologous amino acids in the C terminus,
which is missing helices 11 and 12 of hGR (3). Consequently,
hGR cannot form a stable complex in the ligand binding pocket,
does not bind glucocorticoid agonists, and cannot directly activate
glucocorticoid-responsive reporter genes (4, 5). However, when
coexpressed with hGR in cell culture, hGR demonstrated a
dominant-negative effect on GR-induced transcription activity
(5, 6). Importantly, expression of hGR is selectively induced by
proinflammatory cytokines, and the increased expression of
hGR has also been correlated with the attenuation of hGR sig-
naling activity and the development of glucocorticoid resistance
in many inflammatory diseases (7). hGR has also been shown to
be the predominant GR isoform expressed during inflammation
in cell culture (7, 8). Furthermore, a polymorphism in hGR that
leads to its overexpression has strong associations with human
inflammatory diseases (9, 10). Epidemiological studies have
shown that this polymorphism in hGR is also associated with the
alteration of glucose and lipid homeostasis by glucocorticoids.
Several mechanisms have been proposed to explain the antago-
nismmediated by hGR, including competition for the glucocor-
ticoid response element (GRE), formation of inactive GR/GR
heterodimers, and competition for transcriptional coregulators to
form a transcription complex in the promoter region of target
genes (2).
Using genome-wide microarray analysis on cells selectively
overexpressing hGR, recent studies have discovered that hGR
also has intrinsic transcriptional activities and directly modulates
Received 30 September 2015 Returned for modification 12 November 2015
Accepted 2 December 2015
Accepted manuscript posted online 28 December 2015
Citation He B, Cruz-Topete D, Oakley RH, Xiao X, Cidlowski JA. 2016. Human
glucocorticoid receptor  regulates gluconeogenesis and inflammation in mouse
liver. Mol Cell Biol 36:714–730. doi:10.1128/MCB.00908-15.
Address correspondence to John A. Cidlowski, cidlows1@niehs.nih.gov.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
crossmark
714 mcb.asm.org March 2016 Volume 36 Number 5Molecular and Cellular Biology
the expression profiles of a large number of genes when hGR is
transfected into cells that do not contain hGR (6, 7). In addition,
we have shown that, despite the lack of helix 12 in its ligand bind-
ing domain, hGR binds the antiglucocorticoid compound
RU486 (mifepristone) but not glucocorticoid agonists. Binding of
RU486 with hGR diminishes many changes in gene expres-
sion regulated by hGR expression in U2 OS cells (11). These
in vitro studies suggested that hGR can indeed function as a
transcription factor and regulate glucocorticoid responses
through genomic actions distinct from its antagonism of GR
in the context of a transformed cell line. In the present studies,
our goal was to understand the contributions of hGR to the
actions of glucocorticoids in mice and to further define mecha-
nisms of hGR regulation of gene expression. To accomplish this
goal, we utilized an adeno-associated virus (AAV)-mediated gene
delivery system under the control of the liver-specific human 1-
antitrypsin (hAAT) promoter to achieve hepatocyte-specific
hGR expression in both C57BL/6 wild-type (WT) and GR liver
knockout (GRLKO)mice. Our approach resulted in hGR-spe-
cific expression in the livers of 3-month-old mice as early as 4
weeks after intravenous AAV injection. Genome-wide expres-
sion analysis showed that hGR significantly increased the ex-
pression of numerous genes in the AAV-hGR-injected WT
mouse livers, many of which are involved in endocrine system
disorders, immunological disease, and inflammatory response.
In animals harboring wild-type glucocorticoid receptor in the
liver, hGR antagonized GR’s function and attenuated he-
patic gluconeogenesis through downregulation of phosphoe-
nolpyruvate carboxykinase (PEPCK). However, this repression
did not occur in the livers of GRLKO mice. hGR also had
distinct intrinsic biological activity in both mouse models, as re-
flected by its binding to the intergenic GRE of the signal trans-
ducer and activator of transcription 1 (STAT1) gene and inducing
STAT1 transcription in the liver. Our results reveal a scenario of
GR-dependent and -independent transcriptional activity of
hGR in vivo.
MATERIALS AND METHODS
AAV vector construction and production.Recombinant hAAT promot-
er-driven Flag-tagged human GR or green fluorescent protein (GFP)
AAV vectors were constructed by the standard cloning protocols. The
vector DNAwas packaged into AAV9 particles by triple-plasmid transfec-
tion of HEK293 cells (12) and purified by polyethylene glycol precipita-
tion followed by CsCl centrifugation (13). DNA dot blots were used to
determine the titers of the purified viral stocks as viral genomes (vg) per
milliliter.
Animals and vector administration. Adult C57BL/6 mice (8 to 10
weeks of age) were purchased from Charles River Laboratories. For gen-
eration of GRLKO mice, loxP sites were inserted into the GR locus and
covered exon 3 and exon 4 on aC57BL/6 background (14).Mice homozy-
gous for the floxed GR allele (GRloxp loxp) were crossed with Albumin-Cre
mice from the Jackson Laboratories. All experimental protocols were ap-
proved by the Animal Review Committee of the National Institute of
Environmental Health Sciences (NIEHS), NIH, and were performed ac-
cording to the guidelines for animal care and use. For vector administra-
tion, C57BL/6 mice were intravenously injected with AAV9-hAAT-Flag-
hGR in 0.1 ml of solution via the retro-orbital venous sinus. Three
differentAAVdosages (lowdose, 11011 vg;mediumdose, 51011 vg;high
dose, 2 1012 vg) were tested in a pilot experiment to determine the optimal
injection dosage. AAV injection with 5 1011 vg resulted in a high level of
hGR expression without producing hepatotoxicity. Therefore, this dosage
was chosen for both AAV9-hAAT-Flag-hGR and AAV9-hAAT-Flag-GFP
in subsequent experiments.
Histology, immunochemistry, andWestern blot analysis. Liver and
other tissues were collected 1month after vector injection. Paraformalde-
hyde-fixed and paraffin-embedded tissues were analyzed by hematoxylin
and eosin (H&E) staining and immunohistochemical staining. Cryosec-
tioned tissues with a thickness of 7mwere analyzed by immunofluores-
cent staining with affinity-purified anti-hGR antibody, BShGR, pre-
pared in our laboratory (15). Radioimmunoprecipitation assay (RIPA)
buffer-lysed tissue extracts were resolved on 4 to 20% or 7.5% SDS-PAGE
gels (Bio-Rad, CA) and transferred onto nitrocellulose membranes (Bio-
Rad, CA). The dilutions of antibodies were as follows: rabbit anti-Flag
(Sigma; F7425), 1:1,000; anti-GR 57, prepared in our laboratory (16),
1:1,000; anti-GR D8H2 (Cell Signaling; 3660), 1:1,000; anti-GAPDH
(anti-glyceraldehyde-3-phosphate dehydrogenase) (Abcam; ab9485),
1:1,000.
Microarray analysis. Gene expression analysis was performed on
RNA from livers from different treatment groups using Whole Mouse
Genome 4-by-44 multiplex format oligonucleotide arrays (Agilent Tech-
nologies; 014868) by following the Agilent 1-colormicroarray-based gene
expression analysis protocol. Briefly, starting with 500 ng of total RNA,
Cy3-labeled cRNA was produced according to the manufacturer’s proto-
col. For each sample, 1.65 g of Cy3-labeled cRNA was fragmented and
hybridized for 17 h in a rotating hybridization oven. The slides were
washed and scanned (Agilent). Data were obtained with the Agilent Fea-
ture Extraction software (v9.5), using the 1-color defaults for all parame-
ters. The Agilent Feature Extraction software performed error modeling,
adjusting for additive and multiplicative noise. The resulting data were
processed using OmicSoft Array Studio (v7.0). Principal-component
analysis (PCA) was performed with all samples and all probes to reduce
dimensionality of the data while preserving the variations in the data sets.
This allowed us to assess the similarities and differences of samples within
a treatment group and between treatment groups. Three biological repli-
cate microarrays were completed for each group. In order to identify
differentially expressed probes, analysis of variance (ANOVA)was used to
determine if therewas a statistical difference between themeans of groups.
Specifically, an error-weighted ANOVA with a P value of0.05 was per-
formed using OmicSoft Array Studio (v7.0) software. As previously de-
scribed (17), the lists of probe sets generated were visually sorted by using
a Venn diagram generator (http://www.bioinformatics.lu/venn.php) and
further analyzed with Pathway Analysis version 6.5 (Ingenuity Systems).
For Ingenuity pathway analysis (IPA), a P value of 0.05 (Fisher exact
test) was used as the cutoff for significant biological functions, networks,
and pathways, and they were ranked by ratio. Canonical pathways were
determined by applying Benjamini-Hochberg multiple-testing
adjustments to the P values. These are represented as q values of0.05 as
an indication of significance.
PTTs. Hepatic gluconeogenesis was estimated using pyruvate toler-
ance tests (PTTs). After 18 h of fasting, mice were intraperitoneally in-
jected with sodium pyruvate in saline (Sigma; P5280; 1.5 g/kg body
weight). Plasma samples were collected to measure circulating glucose
concentrations with a glucometer at 0, 10, 20, 30, 45, 60, 90, and 120 min
following pyruvate injection.
Liver tissueChIP assays.Liver tissue (0.20 g) fromeach treatmentwas
used for chromatin immunoprecipitation (ChIP) assays according to the
protocol of the ChIP assay kit (Millipore; 17-295), with minor modifica-
tions. Briefly, minced liver tissue was cross-linked with 1% paraformalde-
hyde–phosphate-buffered saline (PBS) for 20 min at room temperature.
The liver tissue was then resuspended in SDS cell lysis buffer (Millipore;
20-163; 1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) with proteinase
inhibitor cocktails. After homogenization on ice, the liver chromatin was
sonicated into 200- to 500-bp fragments. Then, 0.15 ml of the chromatin
extracts was diluted in 1.5 ml of ChIP dilution buffer (Millipore; 20-153),
followed by preclearance with 50 l of salmon sperm DNA–protein A-
agarose, 50% slurry (Millipore; 16-157C), for 30min at 4°Cwith rotation.
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Immunoprecipitation was performed with either 5 g rabbit anti-Flag
antibody (Sigma; F7425) or 5 g normal rabbit IgG (Millipore; 12-
370) at 4°C overnight. The immunoprecipitated DNA complex was
pulled down using salmon sperm DNA–protein A-agarose, 50% slurry
(Millipore; 16-157C). After washing and elution, cross-links were re-
versed and the DNA was purified using a MiniElute PCR purification
kit (Qiagen; 28004). The amount of immunoprecipitated DNA was
then quantified using real-time quantitative PCR with corresponding
primer-probe sets custom ordered from Integrated DNA Technologies
(Coralville, IA): forward primer (5=-TTTCACCTAATAACAGCATCG
AC-3), probe (5=-56-fluorescein [=56-FAM]CCGTGGACA-ZEN-GACT
GTACAACAAAGCT-3= Iowa Black FQ [3IABkFQ]-3=), and reverse
primer (5=-CCTGGTGATGATACGCTCATA-3=) to the intergenic GRE
of STAT1; forward primer (5=-GCAAACAGATGCCAGAGAATG-3),
probe (5=-56-FAM-TGTGTTCTG-ZEN-CCTCGGGCTTATGAC-3IAB
kFQ-3=), and reverse primer (5=-GTCTCATGGGTTTACTGAGAGTAG-
3=) to the promoter GRE of STAT1; and forward primer (5=-CTGTTCT
GTCCCTGTGTGATT-3=), probe (5=-56-FAM-AAGCTCCAT-ZEN-CG
GTTCTGGTGCTAC-3IABkFQ-3=), and reverse primer (5=-GATGTATC
CAGTTCGCTTAGGG-3=) to intron 22 GRE of STAT1.
JASPAR CORE database (v5.0) and rVista (v2.0) were used to identify
predicted glucocorticoid receptor binding sites within 8,000 bp upstream
of the transcriptional start site and 8,000 bp downstream of the last exon
of the STAT1 gene.
Luciferase assays. An 700-bp fragment containing the intergenic
GREwas cloned into a luciferase reporter plasmid, pGL4.23 (Promega), in
the forward orientation using the following primers: 5=-CTGCGGTACC
TCTCTTTCCCAGCTGAGGGGGACCGACAGCC-3= and 5=-GCCAGG
TACCAATGGTCTGCACCCCAAGACTTCCATTAC-3=. The sequence
of the construct was confirmed by DNA sequencing.
Cos-1 cells were transiently cotransfected with the luciferase reporter
plasmid described above and AAV-hGR or AAV-GFP plasmid using
FuGene 6 transfection reagent (Promega, Madison, WI).
Twenty-four hours after transfection, the cells were split into a 48-well
plate with fresh medium, followed by overnight treatment with vehicle or
1 M RU486. Subsequently, the treated cells were harvested and lysed in
lysis buffer, and the luciferase activity was measured using the Dual Lu-
ciferase reporter assay (Promega).
Quantitative reverse transcription (qRT)-PCR analysis. Liver sam-
ples were collected from different treatment groups. Total liver RNA was
isolated using a Qiagen RNeasy minikit. The abundance of RNAs was
determined on a 7900HT sequence detection system with predesigned
primer-probe sets from Applied Biosystems (Foster City, CA) according
to the manufacturer’s instructions. The signal obtained from each gene
primer-probe set was normalized to that of the unregulated peptidylpro-
pyl isomerase B (PPIB) housekeeping gene primer-probe set from Ap-
plied Biosystems (Foster City, CA). At least three RNA samples from each
treatment were analyzed with each primer-probe set.
Statistical analysis. Student’s t test and one-way ANOVA with
Tukey’s post hoc analysis were performed to evaluate whether differences
were statistically significant, using GraphPad software. Statistical signifi-
cance was defined as a P value of0.05.
Microarray data accession numbers. The microarray data discussed
have been deposited in NCBI’s Gene Expression Omnibus (GEO) (http:
//www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO accession
numbers GSE75740, GSE75683, GSE75682, and GSE5310 (11).
RESULTS
Specific AAV-hGR gene transfer in mouse liver. The ability of
AAV to infect both dividing and quiescent cells and to persist in an
extrachromosomal state has made it an attractive gene vector for
gene therapy.During infection, the proviral AAVgenome remains
episomal in the nucleus without integrating into the host genome
and thus provides stable gene transfer in many tissues, such as
muscle, heart, liver, and brain (18). Based on a number of phase I
FIG 1 Production and injection of AAV9-hAAT-Flag-hGR into C57BL/6 mice. (A) Flag-tagged hGR or GFP was subcloned into an AAV9 vector. Gene
expression was controlled by the hepatocyte-specific hAAT promoter. Flag-GFP served as a vector control. (B) Transfection of AAV vector, AAV9 packaging
plasmid, andMini-Ad helper plasmid into HEK293 cells was used to produce AAV9-Flag-hGR and AAV9-Flag-GFP. (C) AAVwas intravenously injected into
2-month-old C57BL/6 mice. PBS injection and AAV-GFP injection were used for injection control and AAV vector control, respectively.
He et al.
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and phase II clinical trials of human gene therapy, AAV has been
considered a promising gene therapy vector because of its safety,
low immunogenicity, and long-term gene transfer (19).
In this study, we took advantage of an AAV-mediated gene
transfer method to study the function of hGR in mouse liver, a
classic glucocorticoid-responsive organ (20). We subcloned Flag-
tagged hGR cDNA into anAAVvector carrying liver hepatocyte-
specific hAAT promoter to achieve hepatocyte-specific hGR ex-
pression (Fig. 1). To establish a mouse model with hGR
expression in the liver, we intravenously injected AAV-hAAT-
Flag-hGR, or AAV-hAAT-Flag-GFP as a vector control, into
2-month-old C57BL/6 WT or GRLKO mice via the retro-orbital
venous sinus. AAV typically takes 3 to 4 weeks to trigger transgene
expression after trafficking from the circulation to the nucleus
(18). Efficient gene transfer of hGR was achieved in mouse liver
4 weeks after intravenous AAV injection. When examined by
Western blotting with either anti-Flag antibody or anti-GR spe-
cific antibody 57, expression of hGR was detected in the hGR-
infected liver but not in the livers of the AAV-GFP vector control
group and the PBS control group (Fig. 2A and B). Endogenous
mouse GR (mGR) expression remained unchanged in the
AAV-hGR-treated group compared to the control groups (Fig.
2B). In addition, AAV-hAAT-driven gene transfer was highly liver
specific.Western blotting with Flag tag antibody showed no signal
in other tissues collected from treated animals, such as heart,mus-
cle, lung, kidney, and spleen (Fig. 2C). Finally, immunostaining
with the GR-specific antibody BShGR confirmed hGR gene
transfer in the liver, as hGR resided predominantly in the nu-
cleus (Fig. 2D), which is consistent with previous in vitro studies
(2). These results indicated that AAV-mediated hGR gene trans-
FIG 2 Specific AAV-Flag-hGR gene transfer was achieved in C57BL/6mouse liver 1 month after injection. (A)Western blot of injected liver samples with Flag
tag antibody. Multiple liver samples collected from each treatment group were compared side by side. (B) Western blot of injected liver samples with anti-GR
antibody, which recognizes both GR and GR. The endogenous mGR level remained unchanged when hGR was expressed. (C) Flag tag antibody Western
blot for different tissue samples after injection. (D) Immunostaining of injected liver samples with the GR-specific antibody BShGR. DAPI (4=,6-diamidino-
2-phenylindole) staining shows the nuclei. hGR resides predominantly in the nucleus.
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fer was efficient, robust, and stable in the livers of young adult
mice following intravenous injection, establishing an animal
model for physiological studies of hGR. The high levels of ex-
pression of hGR relative to mGR are consistent with those ob-
served following treatment of human cells with proinflammatory
cytokines (8).
AAV-injected liver was functional after hGR expression.
We subsequently examined whether hGR gene transfer affected
liver physiological function or induced any hepatotoxicity in WT
mice.H&E staining showednormal histology in hGR-expressing
livers, as determined by the absence of fibrosis and necrosis (Fig.
3A). Alanine aminotransferase (ALT) and alkaline phosphatase
(ALP) are liver-specific enzymes. Increased enzyme levels in se-
rum serve as biochemical evidence of liver toxicity and acute he-
patocyte damage. Blood chemistry for liver function showed no
significant difference in either ALT or ALP in the AAV-hGR-
treated group compared to control groups (Fig. 3B). Serum albu-
min, a proteinmade specifically by the liver, and total protein also
remained unchanged (Fig. 3B). These data suggested that AAV-
hGR-injected liver was functional and not grossly impacted by
the expression of hGR.
hGR-regulated gene expression profile inWTmouse liver.
The gene regulation profile of hGR in vivo has not been explored.
Therefore, we used a whole-genome microarray approach to
evaluate the gene regulation profile of hGR in mouse liver.
Comparison of significantly hybridized probe sets between
AAV-hGR-injected liver and PBS-injected liver identified
2,108 significantly changed genes after hGR expression, while
AAV-GFP injection resulted in 631 genes being significantly
changed. By comparing these two sets of data (AAV-hGR–
PBS compared to AAV-GFP–PBS), we detected 1,916 genes
specifically regulated by the expressed hGR (Fig. 4A, left). The
192 common genes likely represent AAV backbone effects on
liver gene expression. Of the 1,916 genes, about 90% showed
upregulation of gene expression (Fig. 4A, right). In order to
evaluate the possible phenotypes of the 1,916 genes specifically
FIG 3 Expression of hGR in hepatocytes does not alter normal liver morphology. (A) H&E staining was used to evaluate histology of treated livers. No fibrosis
or necrosis was observed. (B) Serum ALT, ALP, albumin (ALB), and total protein (Tpro) were tested for different groups of wild-type mice. No significant
difference was found among groups for each evaluation. The error bars indicate standard errors of the means (SEM).
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regulated by hGR in the context of the available literature, we
employed IPA. The hGR-regulated genes were most signifi-
cantly associated with endocrine system disorders, gastrointes-
tinal disease, immunological disease, metabolic diseases, and
inflammatory response (Fig. 4B).
hGR attenuates hepatic gluconeogenesis through down-
regulationofPEPCK inWTliver.Given thepredicted association
of hGR-regulated genes with endocrine system disorders and
metabolic disease, we examined whether injection of AAV-hGR
altered the classic gluconeogenic action of glucocorticoid in liver.
Pyruvate tolerance tests performed on fasted mice revealed that
hGR expression in the livers of WT mice significantly decreased
hepatic gluconeogenesis at 45 min, 60 min, and 90 min after py-
ruvate injection compared to control animals. These data were
similar to those observed in adrenalectomized (ADX)mice, which
are devoid of the endogenous glucocorticoid receptor ligand cor-
ticosterone (Fig. 5A).
Based on these findings, we investigated themolecular basis for
hGR attenuation of hepatic gluconeogenesis. The rate of hepatic
glucose production is tightly controlled by the key enzyme
PEPCK. Glucocorticoid activity through GR is well known to
stimulate gluconeogenesis by directly upregulating PEPCK (21).
qRT-PCR showed that AAV-hGR injection significantly down-
regulated PEPCK gene expression. As expected, PEPCK also de-
creased in liver samples from ADX animals (Fig. 5B).
Distinct canonical pathways regulated by hGR inWT liver.
Further IPA analysis of the 1,916 hGR-regulated genes identified
the most significantly affected canonical pathways after AAV-
hGR gene transfer in liver. The significantly regulated pathways
were ranked based on the q value and gene ratio. The highest-
ranked pathways are summarized; they included communication
between innate and adaptive immune cells, granulocyte adhesion
and diapedesis, the role of pattern receptors in recognition of bac-
teria and viruses, interferon (IFN) signaling, and cross talk be-
tween dendritic cells and natural killer cells (Table 1). The associ-
ation of these canonical pathways with innate and adaptive
immunity suggests that glucocorticoid-regulated immune signal-
ing in mouse liver was significantly affected by hGR expression.
FIG 4 Genome-wide microarray analysis of livers from wild-type C57BL/6 mice expressing hGR. The total RNA isolated from each group of C57BL/6 was
applied to an Agilent whole-mouse one-color array. (A) Venn diagrams of AAV-GFP-regulated genes (left) and AAV-hGR-regulated genes (right). The
common part (192 genes) likely reflects AAV backbone effect. The unique part (1,916 genes) of AAV-hGR represents hGR-regulated genes, about 90% of
which are upregulated (up arrow). (B) Ingenuity pathway analysis predicted the top biological functions of hGR-regulated genes.
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The IFN signaling pathway is a well-known target for gluco-
corticoid inhibition, and previous studies showed that glucocor-
ticoids inhibit type I and type II IFN signaling, which contributes
to the immunosuppressive action of glucocorticoids. Specifically,
glucocorticoids inhibit type I and II IFN-induced STAT1 expres-
sion and activation in macrophages at physiological concentra-
tions (22, 23). Thus, we overlaid the hGR-specifically regulated
genes on the interferon signaling pathway and found that IFN-
/, IFN-, STAT1, suppressor of cytokine signaling 1 (SOCS1),
and some interferon-stimulated genes (ISG) were upregulated in
liver expressing hGR (Fig. 6A). In order to determine if the AAV
backbone alone had any effect on interferon activation, we also
overlaid the AAV-GFP data set on the IFN signaling pathway and
found no changes in gene expression, except that IFN-/ expres-
sion was downregulated (Fig. 7A), suggesting the AAV backbone
(AAV-GFP) alone did not activate the interferon signaling path-
way. We thus used qRT-PCR to validate gene alterations detected
bymicroarray. In agreement withmicroarray analysis, the relative
levels of IFN-1, IFN-, STAT1, and SOCS1 mRNAs were all
significantly increased in AAV-hGR-injected liver compared to
AAV-GFP-injected liver, while the mRNA levels of IFN receptors
(IFN-R1, IFN-R2, and IFN-R2) remained unchanged (Fig.
6B). These data demonstrate that hGR expression in hepatocytes
upregulates type I and II IFN and STAT1 gene expression in
mouse liver, implying a proinflammatory function. The increased
expression of SOCS1, which functions in a negative-feedback loop
to repress inflammatory responses, including STAT activation
(24), is likely a secondary response to the increased proinflamma-
tory signaling after hGR expression.
Does hGR regulate gene expression in both GR-depen-
dent and -independentmanners?The ability of hGR to regulate
gene expression has largely been attributed to its antagonism of
hGR (25). However, a recent in vitro study from our laboratory
has shown that hGR also has intrinsic and GR-independent
transcription activity in the context of a cell culture model system
(11). Thus, our next goal was to determine the mechanisms by
which hGR regulates gene expression in vivo. For the experi-
ments, we intravenously injected AAV-hAAT-Flag-mGR or
AAV-hAAT-Flag-hGR, or AAV-hAAT-Flag-GFP as a vector
control, into 2-month-old GRLKOmice. Expression of mGR in
the livers of GRLKOmice was achieved 1 month after AAV injec-
tion (Fig. 8A). GRLKO mice showed only minimal expression of
endogenous GR, which likely reflects its expression from cells
other than hepatocytes in liver, such as immune cells (Fig. 9). Both
WT and mGR-injected GRLKO mice were treated for 6 h with
the synthetic glucocorticoid dexamethasone (DEX). Microarray
FIG 5 hGR expression in wild-type livers attenuates hepatic gluconeogenesis through downregulation of PEPCK. (A) Blood glucose profiles of PTTs. Two
months after AAV injection, blood glucose levels were determined after 18 h of fasting. hGR expression significantly decreased hepatic gluconeogenesis at 45
min, 60 min, and 90 min after pyruvate injection in the wild-type livers compared to the wild-type controls (n	 6; P 0.05). (B) RT-PCR analysis of PEPCK
frommouse livers. hGR expression significantly downregulated PEPCK gene expression in wild-type livers compared to wild-type controls (n	 6; P 0.05).
The error bars indicate standard errors of the means.
TABLE 1 Identification of top canonical pathways of hGR-regulated liver genes in mice
Mice and rank Canonical pathway q valuea Ratio (%)
C57BL/6
1 Communication between innate and adaptive immune cells 4.85E
3 20/89 (22.5)
2 Granulocyte adhesion and diapedesis 1.27E
2 29/177 (16.4)
3 Role of pattern recognition receptors in recognition of bacteria and viruses 1.27E
2 23/126 (18.3)
4 Interferon signaling 3.26E
2 10/36 (27.8)
5 Cross talk between dendritic cells and natural killer cells 3.60E
2 17/89 (19.1)
GRLKO
1 Interferon signaling 4.15E
6 15/36 (41.7)
2 Activation of interferon regulatory factor (IRF) by cytosolic pattern recognition receptors 1.62E
3 16/63 (25.4)
3 Death receptor signaling 1.05E
2 18/92 (19.6)
4 Role of pattern recognition receptors in recognition of bacteria and viruses 1.05E
2 22/126 (17.5)
5 Mitotic roles of polo-like kinase 1.97E
2 14/66 (21.2)
a q value, Benjamini-Hochberg multiple-testing adjusted P value.
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FIG 6 (A) Upregulation of type I and II IFN, STAT1, and SOCS1 gene expression in wild-typemouse liver expressing hGR. The total liver RNA extracted from
each group was applied to an Agilent whole-mouse one-color array and used for RT-PCR. The interferon signaling pathway was changed after AAV-hGR
injection. Gene sets in hGR-injected liver were overlaid on the interferon signaling pathway. Interferon, STAT1, SOCS1, and some interferon-stimulated genes
were upregulated. Red represents upregulated genes. (B) RT-PCR confirmed the upregulation of genes shown in panel A. Relative RNA values were normalized
to PPIB. STAT1, SOCS1, IFN-1, and IFN- and were significantly increased in the AAV-hGR-treated group compared to the control group. No significant
change was found in IFN-R, IFN-R, and IFN-R2 (*, P 0.05). The error bars indicate standard errors of the means.
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analysis revealed that a majority of DEX-responsive genes (2,192/
2,402) in WT mice are regulated by GR (Fig. 8B, left), and rein-
stallation ofmGR in the GRLKOmice recoveredmore than 65%
(1,562/2,402) of DEX-responsive genes seen inWTmice (Fig. 8B,
right). Given the diversity of cell types in the liver, these findings
suggest that we achieved a significant rescue of function in the
livers of GRLKO mice (Fig. 8B, right).
Our next objectivewas to express hGR in the livers ofGRLKO
FIG 7 AAV backbone alone has no effect on interferon activation. Total liver RNA isolated from each group of injected mice was applied to an Agilent
whole-mouse one-color array. Data sets of AAV-GFP/PBS from C57BL/6 (A) and GRLKO (B) mice were overlaid on the IFN signaling pathway in IPA.
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mice. Expression of hGR was detected in the hGR-infected
GRLKO liver 1 month after injection but not in the livers of the
AAV-GFP vector control group and the PBS control group
(Fig. 10 A). Blood chemistry for liver function showed no signifi-
cant difference in the AAV-hGR-treated group compared to
control groups (Fig. 10B). We again used a whole-genome mi-
croarray approach to evaluate the gene regulation profile of hGR
in GRLKOmouse liver.Microarray analysis identified 1,670 genes
specifically regulated by the expression of hGR in the livers of
GRLKO mice, about 60% of which were upregulated (Fig. 10C).
IPA analysis predicted the functional relevance of these hGR-
specifically regulated genes in GRLKO mice. hGR-regulated
genes were most significantly associated with cancer, gastrointes-
tinal diseases, infectious diseases, endocrine system disorders, and
immunological disease (Fig. 10D).
Pyruvate tolerance tests on GRLKO mice demonstrated that
reinstallation ofmGR in liver by AAV rescued hepatic gluconeo-
genesis. In contrast to our findings in hGR-injected WT mice
(Fig. 5A), hGR had no effect on hepatic glucose production in
GRLKOmice (Fig. 10E). These data suggest that hGRmay inter-
fere with hepatic glucose production only in the presence of GR
and not in its absence. The GRLKO mice also had decreased
PEPCK expression, and AAV-mGR injection rescued this phe-
notype, further delineating a critical role of GR in regulating the
FIG 8 mGR reinstallation in livers of GRLKOmice. (A) Two-month-old GRLKOmice were injected with PBS (n	 8), AAV-GFP (n	 8), and AAV-mGR
(n 	 8). A liver Western blot with anti-GR antibody (D8H2), which recognizes both GR and GR, showed that AAV-mGR gene transfer was achieved in
GRLKOmouse liver 1 month after injection. Liver samples collected from each treatment group were compared side by side. (B) Determination of endogenous
GR-regulated genes (left) and comparison of AAV-GR-regulated genes and endogenous GR-regulated genes (right) in mouse liver. Total RNA was isolated
from each group of wild-type and GRLKOmice treated with DEX or vehicle and applied to an Agilent whole-mouse one-color array. The Venn diagram on the
left shows 2,192 endogenousGR-regulated genes, and theVenndiagramon the right shows that 65% (1,562/2,402) of endogenousGR-regulated genes overlap
exogenous mGR-regulated genes.
FIG 9 Immunohistochemical staining of glucocorticoid receptor in mouse liver sections counterstained with hematoxylin. Glucocorticoid receptor was found
in hepatocytes in wild-type mice (A) but not in hepatocytes in GR liver-specific knockout mice (B).
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FIG 10 hGR gene regulation profile in GRLKOmice. Two-month-old GRLKOmice were injected with PBS (n	 8), AAV-GFP (n	 8), and AAV-hGR (n	
8). (A) Western blotting of the indicated liver samples was performed 1 month after injection with anti-GR antibody (D8H2), which recognizes both GR and
GR. Liver samples collected from each treatment group were compared side by side. (B) Serum ALT, ALP, ALB, and Tpro were tested for different groups of
GRLKO mice. No significant difference was found among the groups for each test. (C) Total RNA isolated from each group of GRLKO mice 1 month after
injection was applied to an Agilent whole-mouse one-color array. Shown are Venn diagrams of AAV-GFP-regulated genes (left) and AAV-hGR-regu-
lated genes (right). The common part (330 genes) indicates AAV backbone effect. The unique part (1,670 genes) of AAV-hGR represents hGR-
regulated genes in GRLKO mice, about 60% of which are upregulated. (D) Ingenuity pathway analysis predicted the top biological functions of
hGR-regulated genes in GRLKO. (E) Blood glucose profiles of PTTs in GRLKO mice. Two months after AAV injection, blood glucose levels were
determined after 18 h of fasting. hGR expression did not significantly affect hepatic gluconeogenesis compared to other GRLKO controls (n 	 6). (F)
RT-PCR analysis of PEPCK from GRLKO livers. hGR expression does not significantly change PEPCK gene expression in GRLKO livers compared to
other GRLKO controls (n 	 6; P  0.05). The error bars indicate standard errors of the means.
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expression of the gene. In contrast, AAV-hGR injection had no
effect on PEPCK expression in the absence of endogenous mGR
(Fig. 10F). Taken together, our findings in WT and GRLKOmice
indicated that hGR decreases PEPCK expression and attenuates
hepatic gluconeogenesis in a GR-dependent manner.
Interestingly, immunological disease was revealed in hGR-
expressing livers in both GRLKO mice (Fig. 10D) and WT mice
(Fig. 4B), and IFN signaling was also one of the highest-ranked
canonical pathways significantly affected by hGR in both
GRLKO and WT livers (Table 1). Thus, we overlaid the genes
specifically regulated by hGR in the GRLKO mice on the IFN
signaling pathway and found that IFN-/ and STAT1 were also
upregulated in the GR-deficient liver expressing hGR (Fig.
11A). The AAV backbone (AAV-GFP) alone did not activate the
IFN signaling pathway in GRLKO mouse liver (Fig. 7B). Valida-
tion by RT-PCR showed that the relative mRNA levels of IFN-1
and STAT1 were significantly increased in AAV-hGR-injected
liver compared to AAV-GFP-injected liver in GRLKO mice (Fig.
11B). This effect is very similar to the response to hGR expres-
sion in the livers of wild-type mice. These findings indicate that
hGR regulation of STAT1 gene expression is GR independent.
Previously, we have shown that RU486 has an antagonistic effect
FIG 11 The interferon signaling pathway was altered after hGR expression in GRLKO liver. Two-month-old GRLKO mice were injected with PBS (n 	 8),
AAV-GFP (n 	 8), and AAV-hGR (n 	 8). The total RNA isolated from each group of GRLKO mice 1 month after injection was applied to an Agilent
whole-mouse one-color array. (A) IFN-/, STAT1, and STAT2were increased in the IFN signaling pathway after AAV-hGR injection. Red and green represent
upregulated and downregulated genes, respectively. (B) Prior to sacrifice, the mice in each group were treated with either RU486 (n 	 4) or vehicle (n 	 4)
overnight. Liver RNA was extracted for RT-PCR. Relative RNA values were normalized to PPIB. IFN-1 and STAT1 were significantly increased in the
AAV-hGR-treated group compared to the control group, but these effects were blocked byRU486 treatment. *,P 0.05. The error bars indicate standard errors
of the means.
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on hGR-mediated gene regulation in vitro (11). Therefore, we
next treated the injected GRLKO mice with RU486. The upregu-
lation of STAT1 by hGR was blocked, suggesting RU486 can
specifically regulate the transcriptional activity of hGR in vivo
(Fig. 11B). In summary, hGR regulates gene expression in the
mouse liver in both GR-dependent and -independent fashions.
hGR regulates STAT1 gene expression by binding to inter-
genic GRE.Glucocorticoid receptor regulates the transcription of
many target genes by directly binding to the specific sequences of
DNAknown asGREs (26). In order to define themolecularmech-
anisms underlying the upregulation of STAT1 by hGR in the
liver, we performed liver tissue ChIP assays to investigate whether
hGR was recruited to the GRE of STAT1 in its native chromatin
context. In silico analysis of the STAT1 gene and its adjacent se-
quences identified three putative GREs that showed high homol-
ogy to the consensus GRE and were conserved across species: a
promoter GRE (2,665 bp upstream of exon 1), an intron 22 GRE
(24 bp upstream of exon 23), and an intergenic GRE (3,923 bp
downstream of terminal exon 25). No significant enrichment of
hGR was found at the promoter GRE or intron 22 GRE com-
pared to the controls in the GRLKO liver (Fig. 12A and B). How-
ever, hGR was significantly recruited to the intergenic GRE
located downstream of the STAT1 gene in the AAV-Flag-
hGR-injected liver compared to the AAV-Flag-GFP-injected
liver (Fig. 12C). Moreover, this binding was inhibited after
RU486 treatment (Fig. 12C). These findings were consistent with
our finding that the upregulation of STAT1 by hGRwas reversed
by RU486 in the livers of GRLKO mice.
To determine if the intergenic GRE identified downstream of
the STAT1 gene functioned as an hGR-dependent enhancer in a
heterologous system, we cloned an700-bp fragment containing
the intergenic GRE into a luciferase reporter plasmid, pGL4.23.
Cos-1 cells were transfected with the reporter plasmid and AAV-
hGR or AAV-GFP plasmid as a control, and luciferase activity
was measured after treatment with vehicle or RU486. hGR ex-
pression significantly stimulated luciferase expression, 3 times
higher than theGFP control. This activitywas partially reversed by
the treatment of cells with RU486 (Fig. 12D). Collectively, our
results demonstrated that hGR binds to the intergenic GRE of
STAT1 and induces its gene transcription in the livers of GRLKO
mice.
Comparison of hGR-regulated genes in wild-type and
GRLKO mice. Finally, in order to understand the extent of
GR-dependent and GR-independent transcriptional regula-
tion by hGR in liver, we compared hGR-specifically regu-
lated genes in wild-type mice (1,916) and GRLKO mice
(1,670). We found there are 257 common genes, including the
STAT1 gene, which likely accounts for the intrinsic gene-tran-
scriptional activity of hGR (Fig. 13A). These common genes
were most significantly associated with endocrine system dis-
orders, gastrointestinal diseases, immunological disease, met-
abolic diseases, and antimicrobial response (Fig. 13B). The ma-
jority of the hGR-regulated genes in WTmice (1,659) depend
on the presence of mGR and are associated with diseases and
disorders similar to those observed for the common genes (Fig.
13B and C). Unexpectedly, many of the hGR-regulated genes
FIG 12 Recruitment of hGR to a conserved and functional GRE of the STAT1 gene. Two-month-old GRLKOmice were injected with PBS (n	 8), AAV-GFP
(n	 8), or AAV-hGR (n	 8). Prior to sacrifice, the mice of each group were treated with either RU486 (n	 4) or PBS (n	 4) overnight. ChIP assays with 0.2
g liver tissue were performed with equivalent amounts of IgG and anti-Flag antibodies. (A to C) Coimmunoprecipitated DNAwas analyzed by quantitative PCR
using primers to a promoter GRE of STAT1 (A), an intron-22 GRE of STAT1 (B), and an intergenic GRE of STAT1 (C). The results are plotted as a function of
input DNA. The error bars represent standard errors of the means for three independent experiments. *, P 0.05; n	 4. (D) Luciferase reporter assays were
performed in Cos-1 cells transfected with the reporter plasmid containing the putative GRE and AAV-hGR or AAV-GFP plasmid as a control. hGR binding
to the intergenic GRE of the STAT1 gene significantly induced luciferase expression, but this activity was partially reversed by treatment of the cells with RU486
(1 M).
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in the GRLKO mice (1,413) depend on the loss of mGR, sug-
gesting hGR gains the ability to regulate many genes when
mGR expression is deficient. The annotations most signifi-
cantly associated with this set of unique genes showed almost
no overlap with the unique genes regulated by hGR in WT
mice, indicating the genes are involved in distinct biological
functions (Fig. 13C and D and Table 2).
DISCUSSION
In contrast to the classic and well-studied GR, the physiology
and pathophysiology of the splice variant hGR has been stud-
ied only in vitro. Based on results from in vitro studies, the
dominant-negative effect of GR on GR-induced transcrip-
tion activity has prevailed in the field for many years, suggest-
ing that alterations in the expression level of the splice variant
may regulate cellular sensitivity to glucocorticoids (25). In-
deed, in vitro studies have indicated that changes in the ratio
of cellular GR to GR contribute to glucocorticoid resistance.
Additionally, some patients with glucocorticoid-resistant forms of
asthma, leukemia, and other diseases present with elevated levels
of hGR (7), and polymorphisms in hGR that lead to its over-
expression have strong associations with human inflammatory
diseases (9, 10). Recently, by using microarray techniques, ge-
nome-wide expression analyses were conducted in culturedHeLa,
Cos-1, andU-2OS cells overexpressing yellow fluorescent protein
(YFP)-hGR or GFP-hGR fusion protein. hGR positively or
negatively regulated the expression of a large number of genes, the
majority of which were distinct from genes modulated by GR.
These in vitro results suggested that GR can have intrinsic gene-
specific transcription activities in a GR-independent fashion (6,
11). However, a limitation of these studies is the fact that the
fluorescent protein is relatively large and may affect the hGR
spatial structure and biological function. In addition, although
expression profiling of cultured cells is informative, it cannot cap-
ture the complex cross talk between cells and functional links be-
FIG13 Comparison of hGR-specifically regulated genes in the livers of wild-type andGRLKOmice. Two-month-oldwild-type andGRLKOmicewere injected
with PBS (n 	 8), AAV-GFP (n 	 8), and AAV-hGR (n 	 8). The total RNA isolated from each group 1 month after injection was applied to an Agilent
whole-mouse one-color array. (A) Venn diagrams of hGR-specifically regulated genes in wild-type and GRLKOmice. Only 257 genes overlapped. The unique
hGR-regulated genes in wild-type and GRLKO mice numbered 1,659 and 1,413, respectively. (B) Ingenuity pathway analysis predicted the top diseases and
disorders of hGR-regulated common genes (257). (C) Ingenuity pathway analysis predicted the top diseases and disorders of hGR-regulated unique genes in
wild-type mice (1,659). (D) Ingenuity pathway analysis predicted the top diseases and disorders of hGR-regulated unique genes in GRLKO mice (1,413).
TABLE 2 Diseases and functions of hGR-regulated unique genes in
wild-type and GRLKO mice
Rank
Disease or function
Wild-type mice GRLKO mice
1 Cellular function and maintenance Cancer
2 Cell-to-cell signaling and interaction Gastrointestinal disease
3 Inflammatory response Cell cycle
4 Hematological system development Infectious disease
5 Tissue morphology Gene expression
6 Cell death and survival Organismal survival
7 Endocrine system disorders Embryonic
development
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tween organs in vivo. In order to elucidate the molecular mecha-
nism and physiological role of hGR action, development of a
mouse model expressing hGR is urgently needed.
Viral gene vectors are commonly used to deliver exogenous
genetic materials into cells or tissues for the purpose of either
transient or permanent transgene expression. Among various vec-
tor systems used to date, vectors based onAAVwere chosen in our
study for specific hGR gene transfer in mouse liver because AAV
vector is generally considered to be nonpathogenic, transduces
both dividing and nondividing cells, and confers long-term and
stable gene transfer in vivo without integrating into the chromo-
some.Moreover, in contrast to other viral systems, such as adeno-
viral and retroviral vectors, the AAV vector has demonstrated
successful gene transfer in hepatocytes without inducing immu-
nological complications in amousemodel. Extensive studies have
demonstrated liver immune tolerance of both AAV-encoded
transgene products and AAV capsids (27).
As ametabolic and immunological organ, the liver is a classical
target for glucocorticoids. In order to evaluate hGR’s physiolog-
ical role in liver, we designed and produced AAV9 carrying a Flag-
tagged hGR expression cassette under the transcriptional con-
trol of the hepatocyte-specific hAAT promoter. We intravenously
injected AAV9-hAAT-Flag-hGR into 2-month-old mice and
created an hGR expression mouse model. Consistent with the
canonical view, hGR appeared to reside predominantly in the
hepatocyte nuclei of the injectedmice. Furthermore, blood chem-
istry and histology evidence showed normal liver function after
AAV-hGR injection. Our previous studies demonstrated that
proinflammatory cytokines led to increased hGR expression and
that hGR can even become the predominant GR isoform in cells
during inflammation (8). Thus, our hGR mouse model is an
important tool for studying the function of hGR in the liver.
In vitro studies demonstrated that hGR functions as a domi-
nant-negative inhibitor and antagonizes the activity of GR on
many glucocorticoid-responsive target genes (28, 29). Mecha-
nisms proposed to explain this GR function include competition
for GRE binding through their shared DBD, formation of inactive
GR/GR heterodimers, and competition for transcriptional co-
regulators to form a transcription complex in the promoter region
(30). Our microarray analysis of liver RNA from the injected WT
mice showed that about 90% of hGR-regulated genes were up-
regulated. Many of these regulated genes were significantly asso-
ciated with endocrine system disorders, gastrointestinal disease,
immunological disease, metabolic diseases, and inflammatory re-
sponse, most of which are classical functions of GR. Compared
to the hGR-regulated genes (1,733) previously observed in U2
OS cells in our in vitro study, we found about 10%of the genes in
common (Fig. 14), which likely reflects the different gene regula-
tion profiles of hGR between mouse liver and a cultured trans-
formed human bone cell line.
In addition, in theGRLKOmouse, hGR-regulated geneswere
also significantly associated with endocrine system disorders. The
involvement of GR in liver glucose metabolism has been estab-
lished for a long time. In particular, hepatic gluconeogenesis is
essential formaintenance of blood glucose levels in a normal range
after prolonged fasting (31).We found that hGR overexpression
in the livers ofWTmice significantly decreased hepatic gluconeo-
genesis, while hGR did not have this effect in the livers of
GRLKOmice. PEPCK, the rate-limiting gluconeogenesis enzyme,
was significantly decreased in the hGR-injected WT mice, but
not in the hGR-injected GRLKOmice. These data suggest hGR
attenuated hepatic gluconeogenesis through downregulation of
PEPCK. Importantly, in our hGR C57BL/6 mouse model, the
endogenousmGR expression remained unchanged compared to
AAV-GFP and PBS control groups. These findings suggested that
the dominant-negative effect of hGR on endogenous mGR-
induced transcriptional activity is likely to be the mechanism un-
derlying the alteration of hepatic gluconeogenesis.
In vitro studies using microarray techniques showed that
hGR directly induces and represses the expression ofmany genes
independently of its dominant-negative activity on GR (6, 11).
hGRmay interact with other transcriptional cofactors and tran-
scriptional factors in the nuclear receptor network. Alternatively,
hGR may directly modulate the transcriptional activities of its
responsive genes by binding to specific response elements in the
promoter region of these genes (4). To investigate the gene regu-
lation profile of hGR, we applied the same AAV-mediated gene
transfer approach in GRLKO mice. These knockout mice are
largely devoid not only of mGR but also of a recently described
version of mouse GR (mGR) (32). Importantly, reinstallation
of mGR by AAV in the GRLKOmouse livers rescued more than
65% of DEX-responsive genes in WTmice, as well as hepatic glu-
coneogenesis. AAV-hGR-injected GRLKO mice and AAV-
hGR-injected C57BL/6WTmice shared the immunological dis-
eases and infectious disease or inflammatory response as the top
diseases and disorders, as reflected by the upregulation of STAT1
and IFN-/ in both mouse models after hGR expression. Fur-
thermore, canonical pathway analysis identified the interferon
signaling pathway as one of the most significantly regulated path-
ways in both WT and GRLKO mice injected with AAV-hGR.
These results indicated that hGR directly induces and represses
gene expression in a GR-independent fashion. Therefore, the
intrinsic transcription activity of hGR could be another mecha-
nism underlying the phenotypes observed in the hGR-express-
ing liver. Interestingly, hGR alone regulates many unique genes
(1,413) in the absence of GR (Fig. 13 and Table 2).
We also discovered upregulation of key molecules in the inter-
feron signaling pathway after hGR expression in both GRLKO
FIG 14 Comparison of hGR-regulated genes in GRLKO liver and U2
OS cells published previously. The total RNAs isolated from AAV-hGR-
injected GRLKO liver and that from U2 OS cells were applied to an
Agilent whole-mouse one-color array and a whole-human one-color array,
respectively. Shown are Venn diagrams of AAV-hGR-regulated genes in
GRLKO liver (left) and hGR-regulated genes in U2 OS cells (right).
Only 156 genes overlap.
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andWTmice, such as type I and II interferon, STAT1, and SOCS1.
Our RT-PCR results confirmed that IFN and STAT1 expression
was significantly increased in AAV-hGR-injected mouse liver
compared to that in AAV-GFP-injectedmouse liver. Recent stud-
ies demonstrated that AAV infection of purified hepatic Kupffer
cells in vitro failed to produce significant levels of type I IFN and
interleukin 6 (IL-6), in contrast to infection with adenovirus (33),
and that gene expression of STAT1 and SOCS1 remained un-
changed in AAV-injected mouse liver compared to the control
(34). These findings support our data showing that upregulation
of interferon by hGR is not due to AAV infection of other im-
mune cells in the liver. Previous studies showed that glucocorti-
coids inhibit type I and type II interferon signaling by regulating
STAT1 expression (22, 23). Our current work provides the first
evidence in vivo that hGR may attenuate GR-mediated anti-
inflammatory action by upregulation of many cytokines and
STAT1. Interestingly, in the GRLKOmice, significant enrichment
of hGR was found in the intergenic GRE adjacent to the STAT1
gene in the AAV-Flag-hGR-injected liver compared to the con-
trols. These data indicated that hGR directly regulates the ex-
pression of STAT1, a key proinflammatory signal in liver inflam-
mation, at the transcriptional level. Furthermore, in our GRLKO
mouse model expressing hGR, upregulation of STAT1 by hGR
was blocked after injection of the glucocorticoid receptor antago-
nist RU486, suggesting RU486 antagonized hGR-mediated gene
regulation.
Our studies have demonstrated that hGR possesses both
GR-dependent and GR-independent mechanisms of gene reg-
ulation. In animals harboring wild-type glucocorticoid receptor
in liver, hGR antagonized GR’s function and attenuated he-
patic gluconeogenesis through downregulation of PEPCK. Sur-
prisingly, in animals with decreased levels of endogenous GR in
the liver, we observed that hGR gained the ability to regulate a
large cohort of genes. These findings suggest that GR and GR
can regulate each other via the formation of heterodimers and/or
competition for GRE binding. A greater understanding of the
mechanism underlying hGR transcriptional activity of its re-
sponsive genes is necessary to elucidate the exact role of hGR in
glucocorticoid resistance. This will be of particular interest to peo-
ple with elevated levels of GR due to a polymorphism, A3669G,
in the GR gene (35) or cytokine stimulus (8). RU486 could be a
potential regimen to reverse the undesirable inflammatory effects
of hGR seen in A3669G carriers.
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